EMA clears Oryzon to start Phase IIa HOPE-2 vafidemstat trial
The open-label, single-center study will enroll 12 adults in Spain and can be extended to 24 weeks.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.